This episode demystifies the process for registering an FDA-cleared medical device in China. We explore why FDA approval is only the first step and detail the unique requirements of the National Medical Products Administration (NMPA), including classification, local agent representation, in-country testing, and clinical data validation for the Chinese market. Key Questions: • Is my US FDA clearance sufficient for selling my device in China? • What is an NMPA Legal Agent and why do I need one? • Does my device's risk classification change between the FDA and NMPA? • Will I need to conduct new device testing in a Chinese lab? • Can I use my existing clinical trial data for the NMPA submission? • What is a Product Technical Requirement (PTR) and how is it used? • What are the main challenges when submitting a technical dossier to the NMPA? • How did the October 1, 2021, NMPA provisions change the regulatory landscape? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.